Systemic Lupus Erythematosus Market Size - Global Industry, Share, Analysis, Trends and Forecast 2022 - 2030
The Global Systemic Lupus Erythematosus Market Size accounted for USD 1,951 Million in 2021 and is estimated to achieve a market size of USD 3,517 Million by 2030 growing at a CAGR of 7% from 2022 to 2030. The global rise in the incidence of systemic lupus erythematosus will be a primary driver of the systemic lupus erythematosus market. Furthermore, the growing senior population and growing healthcare spending will drive the systemic lupus erythematosus market value in the coming years.
Systemic Lupus Erythematosus Market Report Key Highlights
- Global systemic lupus erythematosus market revenue is estimated to expand by USD 3,517 million by 2030, with a 7% CAGR from 2022 to 2030.
- North America region accounted for over 51% of the systemic lupus erythematosus market shares in 2021
- Asia-Pacific systemic lupus erythematosus market growth will observe highest CAGR from 2022 to 2030
- Based on drug classes, immunosuppressants segment accounted for over 48% of the overall market share in 2021
- Among route of administration, oral segment engaged more than 53% of the total market share
- Increasing public awareness of inflammatory autoimmune diseases & treatment, drives the systemic lupus erythematosuse market size
Systemic lupus erythematosus is an autoimmune illness that affects all of the body's organ systems. The immune system attacks our body because it considers it foreign, resulting in the emergence of autoimmune illness. People with this illness can lead normal lives. This condition occurs most frequently in women and usually affects women aged 25 to 45. Lupus indications include knee pain, adnominal discomfort, hair loss, kidney difficulties, skin irritation, and headaches, as well as many others.
Global Systemic Lupus Erythematosus Market Trends
Market Drivers
- Rapid spread of systemic lupus erythematosus
- Growing geriatric population
- Increasing healthcare spending for effective treatment
- Increasing public knowledge of inflammatory autoimmune diseases & treatment
Market Restraints
- High cost associated with treatment
- Lack of facilities in low-income countries
Market Opportunities
- Increasing research and development activity
- Effective therapy launches and rising new markets
Systemic Lupus Erythematosus Market Report Coverage
| Market | Systemic Lupus Erythematosus Market |
| Systemic Lupus Erythematosus Market Size 2021 | USD 1,951 Million |
| Systemic Lupus Erythematosus Market Forecast 2030 | USD 3,517 Million |
| Systemic Lupus Erythematosus Market CAGR During 2022 - 2030 | 7% |
| Systemic Lupus Erythematosus Market Analysis Period | 2018 - 2030 |
| Systemic Lupus Erythematosus Market Base Year | 2021 |
| Systemic Lupus Erythematosus Market Forecast Data | 2022 - 2030 |
| Segments Covered | By Drug Classes, By Route of Administration, And By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Roche, Sanofi, GlaxoSmithKline, Pfizer, Bayer, Astra Zeneca, Novartis, ImmuPharma, and Aurinia Pharmaceuticals |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
Biologics for autoimmune conditions enhance treatment to a huge extent and are progressively gaining physicians’ confidence. Benlysta, the principal biologic in the previous five decades, was endorsed by the FDA and EMA in 2011. Nonetheless, in nations, for example, the U.K., it was first rejected on grounds of horrible money-saving advantage examination and later propelled in the year 2016, however with value concessions. Low to direct adequacy of Benlysta towards patients determined to have serious fundamental lupus erythematosus (SLE), including Lupus Nephritis, is noteworthy confinement deflecting market reception. Henceforth, GSK is attempting clinical preliminaries to decide the consolidated adequacy of Benlysta and rituximab, so as to support the appropriation of its treatments in the market.
Systemic Lupus Erythematosus Market Insights
The introduction of new natural or biological treatments, which will add to treatment options and drug costs, in the advancement pipeline is evaluated to fuel the income age of the market. Certain new encouraging medications that are as of now in Phase III preliminaries are foreseen to enlarge the market as these medications may focus on the lupus nephritis tolerant subset with a couple of compelling options and noteworthy neglected should be met. This factor is probably going to strongly affect the market as almost 50.0% of SLE patients endure lupus nephritis.
Utilization of approved biologic, Benlysta, through clinical investigations, has uncovered exceptional upgrades and a considerable decline in utilization of mitigating glucocorticoids in moderate SLE cases. GSK's present activities fixate on further expanding open doors for Benlysta. The organization is leading sign extension clinical preliminaries, mix treatment examines with rituximab, and new item improvement, to enlarge open doors for its treatment. Toward this path, ongoing dispatch of Benlysta's subcutaneous plan in a few nations is relied upon to help the SLE showcase over the conjecture time frame.
Systemic Lupus Erythematosus Market Segmentation
The worldwide systemic lupus erythematosus market segmentation is based on the drug classes, route of administration, and geography.
Systemic Lupus Erythematosus Market By Drug Classes
- NSAIDs
- Antimalarials
- Corticosteroids
- Immunosuppressants
- Biologics
According to the systemic lupus erythematosus market forecast, the biologics segment is expected to grow the most throughout the forecasted year. The launch of novel biologics with better efficacy is projected to augment the entire market's growth. Benlysta, the first biological drug administration for the treatment of SLE, has won physician trust for minor to moderate SLE. Meanwhile, its safety and effectiveness in the severe form are currently being monitored. Furthermore, some biological medicines, such as rituximab, are utilized as off-label medication for systemic lupus and, unlike corticosteroids as well as immunosuppressants, have no side effects.
Systemic Lupus Erythematosus Market By Route of Administration
- Oral
- Intravenous
- Subcutaneous
According to systemic lupus erythematosus industry analysis, the oral segment dominate the market in 2021. The oral module contains small-molecule medications that are easy to give and continue to be the standard treatment for SLE. Furthermore, during the forecasted years, the subcutaneous segment has been the fastest-growing segment in the market. One of the key growth boosters for the segment is the latest clearance of subcutaneous formulations of Benlysta and rituximab in various countries, including the United States and several European countries.
Systemic Lupus Erythematosus Market Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
North America Holds The Largest Share Of The Global Systemic Lupus Erythematosus Market
North America ruled the market in 2021, with the U.S. at the front line. The district is anticipated to hold its situation through 2030, advancing at a CAGR of 8.2% amid the conjecture time frame. The higher pervasiveness of SLE combined with the inclusion of strong medications and healthcare infrastructure framework is adding to the development of the local market. Europe was the second-biggest territorial market in 2021. This can be ascribed to the way that the five noteworthy European Union nations (Germany, the U.K., Italy, Spain, and France) were the first to support Benlysta as an extra treatment for the treatment of dynamic SLE. Also, because of better inclusion approaches, there is a higher adoption of belimumab since it is accessible in the two details or formulations.
Systemic Lupus Erythematosus Market Players
Some of the top systemic lupus erythematosus market companies offered in the professional report includes Roche, Sanofi, GlaxoSmithKline, Pfizer, Bayer, Astra Zeneca, Novartis, ImmuPharma, and Aurinia Pharmaceuticals.
Frequently Asked Questions
What is the size of global systemic lupus erythematosus market in 2021?
The estimated value of global systemic lupus erythematosus market in 2021 was accounted to be USD 1,951 Million.
What is the CAGR of global systemic lupus erythematosus market during forecast period of 2022 to 2030?
The projected CAGR systemic lupus erythematosus market during the analysis period of 2022 to 2030 is 7%.
Which are the key players operating in the market?
The prominent players of the global systemic lupus erythematosus market are Roche, Sanofi, GlaxoSmithKline, Pfizer, Bayer, Astra Zeneca, Novartis, ImmuPharma, and Aurinia Pharmaceuticals.
Which region held the dominating position in the global systemic lupus erythematosus market?
North America held the dominating systemic lupus erythematosus during the analysis period of 2022 to 2030.
Which region registered the fastest growing CAGR for the forecast period of 2022 to 2030?
Asia-Pacific region exhibited fastest growing CAGR for systemic lupus erythematosus during the analysis period of 2022 to 2030.
What are the current trends and dynamics in the global systemic lupus erythematosus market?
Rapid spread of systemic lupus erythematosus diseases and growing geriatric population drives the growth of global systemic lupus erythematosus market.
By drug classes segment, which sub-segment held the maximum share?
Based on drug classes, immunosuppressants segment is expected to hold the maximum share of the systemic lupus erythematosus market.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
